RETATRUTIDE — 30 MG

Retatrutide is an investigational peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. It is being clinically developed primarily for obesity and associated metabolic conditions. Clinical research has demonstrated substantial effects on body weight and metabolic markers. Retatrutide remains investigational and is not currently FDA-approved. Contains 30 MG per vial.